跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Pyruvate
首页
药物
Pyruvate
Pyruvate
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
PYRUVATE KINASE MODULATORS AND USE THEREOF
EP 3668512 B1
申请人: AGIOS PHARMACEUTICALS INC
优先权: 2017
CN
EP
US
WO
21 件公开
Compositions including pyruvate for companion animals and methods of use thereof
US 8999375 B2
申请人: YAMKA RYAN MICHAEL
优先权: 2010
CN
US
9 件公开
LENTIVIRAL VECTORS FOR DELIVERY OF PKLR TO TREAT PYRUVATE KINASE DEFICIENCY
EP 3697452 A1
申请人: CENTRO DE INVESTIG ENERGETICAS MEDIOAMBIENTALES Y TECNOLOGICAS O A M P
优先权: 2017
CN
EP
US
WO
8 件公开
ACTIVATING PYRUVATE KINASE R
EP 4031132 A4
申请人: FORMA THERAPEUTICS INC
优先权: 2019
CN
EP
US
WO
8 件公开
US 10675274 B2
申请人: FORMA THERAPEUTICS INC
优先权: 2019
US
5 件公开
US 12122778 B2
申请人: NOVO NORDISK HEALTHCARE AG
优先权: 2019
US
2 件公开
US 12128035 B2
申请人: NOVO NORDISK HEALTHCARE AG
优先权: 2022
US
METHODS OF USING PYRUVATE KINASE ACTIVATORS
EP 3307271 B1
申请人: AGIOS PHARMACEUTICALS INC
优先权: 2015
EP
US
WO
8 件公开
US 9388164 B2
申请人: SU SHIN-SAN M
优先权: 2012
US
2 件公开
US 9403792 B2
申请人: SU SHIN-SAN M
优先权: 2012
US
2 件公开
COMPOSITIONS AND METHODS FOR ENHANCED GENE EXPRESSION OF PKLR
EP 3445406 B1
申请人: CENTRO DE INVESTIG ENERGETICAS MEDIOAMBIENTALES Y TECNOLOGICAS O A M P
优先权: 2016
CN
EP
US
8 件公开
PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS
EP 3680241 A1
申请人: FORMA THERAPEUTICS INC
优先权: 2017
CN
EP
US
8 件公开
Pyruvate kinase activators for use in therapy
US 9193701 B2
申请人: SU SHIN-SAN M
优先权: 2012
US
8 件公开
US 9404081 B2
申请人: SU SHIN-SAN MICHAEL
优先权: 2012
CN
US
3 件公开
PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS
EP 4612132 A1
申请人: SITRYX THERAPEUTICS LTD
优先权: 2022
CN
EP
US
WO
7 件公开
US 20260152487 A1
申请人: SITRYX THERAPEUTICS LTD
优先权: 2021
EP
US
2 件公开
US 20250051313 A1
申请人: SITRYX THERAPEUTICS LTD
优先权: 2021
US
CN 118317951 A
申请人: CYTERA THERAPEUTICS INC
优先权: 2022
CN
PYRUVATE KINASE DEFICIENCY (PKD) GENE EDITING TREATMENT METHOD
EP 4172332 A1
申请人: CENTRO DE INVESTIG ENERGETICAS MEDIOAMBIENTALES Y TECNOLOGICAS O A M P
优先权: 2020
CN
EP
US
WO
6 件公开
第 1 / 9 页
上一页
下一页
药物
反馈